Cipla reported INR424.96B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Arca Biopharma USD 504.48M 15.86M Mar/2026
aTyr Pharma USD 79.65M 435.68M Mar/2026
Bio Path USD 677K 13K Mar/2026
Brainstorm Cell Therapeutics USD 755K 267K Mar/2026
Capricor Therapeutics USD 326.28M 29.66M Mar/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Cipla INR 424.96B 23.32B Mar/2026
Dr.Reddys Laboratories INR 575.31B 5.93B Jun/2026
Immunic USD 189.74M 165.69M Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sun Pharmaceuticals INR 1.09T 50.79B Mar/2026
TherapeuticsMD USD 40.13M 1.96M Jun/2024
UPL INR 952.05B 38.14B Mar/2026